MAROKO133 Eksklusif ai: What to be thankful for in AI in 2025 Hari Ini

📌 MAROKO133 Breaking ai: What to be thankful for in AI in 2025 Wajib Baca

Hello, dear readers. Happy belated Thanksgiving and Black Friday!

This year has felt like living inside a permanent DevDay. Every week, some lab drops a new model, a new agent framework, or a new “this changes everything” demo. It’s overwhelming. But it’s also the first year I’ve felt like AI is finally diversifying — not just one or two frontier models in the cloud, but a whole ecosystem: open and closed, giant and tiny, Western and Chinese, cloud and local.

So for this Thanksgiving edition, here’s what I’m genuinely thankful for in AI in 2025 — the releases that feel like they’ll matter in 12–24 months, not just during this week’s hype cycle.

1. OpenAI kept shipping strong: GPT-5, GPT-5.1, Atlas, Sora 2 and open weights

As the company that undeniably birthed the "generative AI" era with its viral hit product ChatGPT in late 2022, OpenAI arguably had among the hardest tasks of any AI company in 2025: continue its growth trajectory even as well-funded competitors like Google with its Gemini models and other startups like Anthropic fielded their own highly competitive offerings.

Thankfully, OpenAI rose to the challenge and then some. Its headline act was GPT-5, unveiled in August as the next frontier reasoning model, followed in November by GPT-5.1 with new Instant and Thinking variants that dynamically adjust how much “thinking time” they spend per task.

In practice, GPT-5’s launch was bumpy — VentureBeat documented early math and coding failures and a cooler-than-expected community reaction in “OpenAI’s GPT-5 rollout is not going smoothly," but it quickly course corrected based on user feedback and, as a daily user of this model, I'm personally pleased with it and impressed with it.

At the same time, enterprises actually using the models are reporting solid gains. ZenDesk Global, for example, says GPT-5-powered agents now resolve more than half of customer tickets, with some customers seeing 80–90% resolution rates. That’s the quiet story: these models may not always impress the chattering classes on X, but they’re starting to move real KPIs.

On the tooling side, OpenAI finally gave developers a serious AI engineer with GPT-5.1-Codex-Max, a new coding model that can run long, agentic workflows and is already the default in OpenAI’s Codex environment. VentureBeat covered it in detail in “OpenAI debuts GPT-5.1-Codex-Max coding model and it already completed a 24-hour task internally.”

Then there’s ChatGPT Atlas, a full browser with ChatGPT baked into the chrome itself — sidebar summaries, on-page analysis, and search tightly integrated into regular browsing. It’s the clearest sign yet that “assistant” and “browser” are on a collision course.

On the media side, Sora 2 turned the original Sora video demo into a full video-and-audio model with better physics, synchronized sound and dialogue, and more control over style and shot structure, plus a dedicated Sora app with a full fledged social networking component, allowing any user to create their own TV network in their pocket.

Finally — and maybe most symbolically — OpenAI released gpt-oss-120B and gpt-oss-20B, open-weight MoE reasoning models under an Apache 2.0–style license. Whatever you think of their quality (and early open-source users have been loud about their complaints), this is the first time since GPT-2 that OpenAI has put serious weights into the public commons.

2. China’s open-source wave goes mainstream

If 2023–24 was about Llama and Mistral, 2025 belongs to China’s open-weight ecosystem.

A study from MIT and Hugging Face found that China now slightly leads the U.S. in global open-model downloads, largely thanks to DeepSeek and Alibaba’s Qwen family.

Highlights:

• DeepSeek-R1 dropped in January as an open-source reasoning model rivaling OpenAI’s o1, with MIT-licensed weights and a family of distilled smaller models. VentureBeat has followed the story from its release to its cybersecurity impact to performance-tuned R1 variants.

• Kimi K2 Thinking from Moonshot, a “thinking” open-source model that reasons step-by-step with tools, very much in the o1/R1 mold, and is positioned as the best open reasoning model so far in the world.

• Z.ai shipped GLM-4.5 and GLM-4.5-Air as “agentic” models, open-sourcing base and hybrid reasoning variants on GitHub.

• Baidu’s ERNIE 4.5 family arrived as a fully open-sourced, multimodal MoE suite under Apache 2.0, including a 0.3B dense model and visual “Thinking” variants focused on charts, STEM, and tool use.

• Alibaba’s Qwen3 line — including Qwen3-Coder, large reasoning models, and the Qwen3-VL series released over the summer and fall months of 2025 — continues to set a high bar for open weights in coding, translation, and multimodal reasoning, leading me to declare this past summer as "

  Qwen's summer."

VentureBeat has been tracking these shifts, including Chinese math and reasoning models like Light-R1-32B and Weibo’s tiny VibeThinker-1.5B, which beat DeepSeek baselines on shoestring training budgets.

If you care about open ecosystems or on-premise options, this is the year China’s open-weight scene stopped being a curiosity and became a serious alternative.

3. Small and local models grow up

Another thing I’m thankful for: we’re finally getting good small models, not just toys.

Liquid AI spent 2025 pushing its Liquid Foundation Models (LFM2) and <a href…

Konten dipersingkat otomatis.

🔗 Sumber: venturebeat.com

📌 MAROKO133 Update ai: Scientists Intrigued by Old Drug That Reverses Signs of Alz

The next new treatment for Alzheimer’s disease may be an already-existing drug, according to a team of researchers in Japan.

In a series of experiments, administering an oral dose of an amino acid called arginine, which is already prescribed to treat high blood pressure, was able to suppress the buildup of a protein associated with Alzheimer’s in mice, the scientists report in a new study published in the journal Neurochemistry International.

“Our study demonstrates that arginine can suppress amyloid-beta aggregation both in vitro and in vivo,” study coauthor Yoshitaka Nagai, neuroscientist at Kindai University, said in a statement about the work. “What makes this finding exciting is that arginine is already known to be clinically safe and inexpensive, making it a highly promising candidate for repositioning as a therapeutic option for Alzheimer’s disease.”

Scientists still don’t understand the underlying cause of Alzheimer’s disease, but amyloid-beta proteins figure somewhere in the question. Though they’re a part of normal brain function, they’re sticky and can clump together to form “plaques” in the brain. These plaques are considered a hallmark of Alzheimer’s, though not all patients with the disease are found to have them.

According to the researchers’ findings, the arginine can help flush these plaques and break them apart. They demonstrated this by feeding mice with amyloid-beta buildup in their brains drinking water and food infused with small doses of the drug.

Along with breaking up the buildup, they also found that the mice which were administered arginine showed improved behavior and cognitive performance, suggesting that the drug helped reverse some of the disease’s harmful effects. This was assessed by analyzing how the mice navigated an elevated Y-shaped maze, noting how far the mice traveled and how many times it entered the maze’s “open arms,” a test of a healthy mice’s natural instinct to avoid open spaces and enter enclosed ones.

Human clinical trials are needed to bear out the medical potential, but the researchers are optimistic.

“Given its excellent safety profile and low cost, arginine could be rapidly translated to clinical trials for Alzheimer’s and potentially other related disorders,” Nagai said in the statement.

Other recent studies have explored promising avenues for treating Alzheimer’s. A team of scientists in China said they were able to almost instantly reverse the disease’s progression using nanoparticles injected in their brains that cleared the plaques and led to cognitive improvements. Another team in Japan used synthetic peptides to reverse progression in early stages of the disease.

Still, amyloid-beta’s function in the brain in general remains a mystery, and so the jury’s still out on whether targeting them is a meaningful way of treating, let alone curing, the tragic disease.

More on Alzheimer’s: Lab Mice Exposed to Microplastics Show Signs of Dementia

The post Scientists Intrigued by Old Drug That Reverses Signs of Alzheimer’s in Mice appeared first on Futurism.

🔗 Sumber: futurism.com